BSX — long thesis
Thesis
Boston Scientific is benefiting from the defensive healthcare rotation in the current rate-shock regime. The company has two significant recent catalysts: advancing coronary calcium treatment with FDA premarket approval, and targeting the growing aortic stenosis market. Healthcare is outperforming (+1.1% today, +1.0% 5d) while tech and discretionary lag. BSX provides medtech exposure — a sub-sector with more predictable revenue streams than pharma (no patent cliff risk like LLY). The rate-shock regime (CPI 3.8%, 30Y at 5.2%) favors defensive healthcare names with procedure-driven revenue rather than high-multiple growth.
Triggers
Entry: Enter on any pullback of 3-5% from current levels, or if the stock consolidates near current levels for 3+ sessions. Position size ~1% of portfolio (~$80). Healthcare rotation confirmation requires sector outperformance for 2+ consecutive weeks.
Exit: Take profits at 12-15% above entry. Exit if healthcare sector underperforms SPY for 3+ consecutive weeks. Trim if position exceeds 2% of portfolio.
Invalidation: FDA safety concerns on coronary calcium or aortic stenosis devices; healthcare sector enters sustained downturn lasting 4+ weeks; stock breaks below recent support on fundamental deterioration; CPI drops sharply below 3% removing the defensive rotation catalyst.
Cited evidence
News
- BSX Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results
- BSX Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal
Macro
- 12 Health Care Stocks Moving In Tuesday's Intraday Session